Breast Cancer Clinical Trial

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

Summary

This is a single arm, phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival in patients with metastatic HER2 positive breast cancer. All patients will be treated with T-DM1 with palbociclib.

View Full Description

Full Description

This is a multi-center, single arm, phase II study of T-DM1 with or without palbociclib in the treatment of patients with metastatic HER2-positive breast cancer.

Hypotheses: Combination of T-DM1 with palbociclib improves progression free survival

Primary objective: Progression free survival of the combination of T-DM1 with palbociclib

Secondary objectives i) Response rates ii) Overall survival

Correlative objectives i) Investigate predictive biomarkers of response in blood and archived tumor tissue ii) Investigate mechanisms of resistance for palbociclib in blood and tumor tissue

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Be informed of the investigational nature of the study and all pertinent aspects of the trial
Sign and provide written consent in accordance with institutional and federal guidelines.
ECOG Performance status of 0-2
Recurrent or metastatic HER2-positive breast cancer (HER2 positive is defined per ASCO-CAP guidelines)
Adequate cardiac reserve (EF≥50%)
Serum creatinine ≤ 1.5 x institutional upper limit of normal (IULN), bilirubin ≤ 2.0, and an SGOT/SGPT/alkaline phosphatase ≤ 2.0 x IULN
Adequate bone marrow function (ANC ≥1000, Platelets ≥100,000/ml, Hemoglobin ≥10gm/dL)
Be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures
Been treated with pertuzumab previously (neoadjuvant or metastatic setting). Patients who weren't able to tolerate pertuzumab due to side effects can be eligible for study upon discussion with the study PI
No more than 2 lines of therapy in the metastatic disease setting

Exclusion Criteria:

HER2 negative tumors
Prior treatment with T-DM1
Prior treatment with CDK 4/6 inhibitors
Known active CNS metastases or carcinomatous meningitis. Patients with stable CNS metastases including brain metastases who have completed a course of radiotherapy are eligible for the study provided they are clinically stable. However, oral corticosteroids for control of CNS symptoms are not allowed on study
Known documented or suspected hypersensitivity to the components of the study drug(s) or analogs.
Uncontrolled systemic illness, including but not limited to ongoing or active infection
Symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months
Be pregnant or breast feeding. Female subjects must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment and must agree to use effective contraception during the period of therapy
Concurrent hormonal or other anti-neoplastic therapy is not allowed. Patients can receive supportive therapy like bone-directed therapy including bisphosphonates or denosumab

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

46

Study ID:

NCT03530696

Recruitment Status:

Active, not recruiting

Sponsor:

University of Arizona

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 16 Locations for this study

See Locations Near You

University of Arizona Cancer Center
Tucson Arizona, 85724, United States
Cedar-Sinai
Beverly Hills California, 90048, United States
University of Colorado Denver
Aurora Colorado, 80045, United States
Yale Cancer Center
New Haven Connecticut, 06519, United States
Johns Hopkins Hospital
Baltimore Maryland, 21287, United States
Mosaic Life Care
Saint Joseph Missouri, 65406, United States
University of New Mexico
Albuquerque New Mexico, 87131, United States
Roswell Park Comprehensive Cancer center
Buffalo New York, 14263, United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill North Carolina, 27599, United States
Cleveland Clinic
Cleveland Ohio, 44195, United States
Oregon Health and Sciences University
Portland Oregon, 97239, United States
Thomas Jefferson University Hospital
Philadelphia Pennsylvania, 19107, United States
JPS Health Network
Fort Worth Texas, 76104, United States
Swedish Cancer Institute
Seattle Washington, 98104, United States
University of Washington
Seattle Washington, 98195, United States
University of Wisconsin
Madison Wisconsin, 53706, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

46

Study ID:

NCT03530696

Recruitment Status:

Active, not recruiting

Sponsor:


University of Arizona

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider